Please assess the completion status of the following clinical trial:

Trial Title: Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) status of 0-3~* Active leukemia and Burkitt leukemia/lymphoma treated in-house that puts them at risk for tumor lysis syndrome (TLS)~* Serum uric acid level \>= 7.5mg/dL and high risk for TLS as defined by:~  * A diagnosis of acute myeloid leukemia (AML), or~ * A diagnosis of blast-phase chronic myeloid leukemia (CML), or~ * A diagnosis of high-grade myelodysplastic syndrome (MDS) with \>= 10% blast bone marrow blast involvement, or~ * Acute lymphoblastic leukemia (ALL), or~ * Burkitt leukemia/lymphoma~* Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure~Exclusion Criteria:~* History of asthma~* History of severe or life threatening atopic allergy~* Hypersensitivity to uricases~* Known prior sensitivity to allopurinol~* Known glucose-6-phosphate dehydrogenase (G6PD) deficiency~* Recent prior history of uricolytic therapy defined as therapy within the last 7 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (1.5mg rasburicase) (Type: EXPERIMENTAL): Patients receive 1.5mg of rasburicase IV over 30 minutes on day 1 and allopurinol PO QD on days 1-6.
- Arm II (3 mg rasburicase) (Type: EXPERIMENTAL): Patients receive 3 mg of rasburicase IV over 30 minutes on day 1 and allopurinol PO QD on days 1-6.

Based on this trial design, predict the completion outcome and termination type (if applicable).